Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants

Pediatrics

Volumn 115, Issue 3, 2005, Pages

  Byung, Min Choi ^a   Kee, Hyoung Lee ^a   Baik, Lin Eun ^a   Kee, Hwan Yoo ^a   Young, Sook Hong ^a   Chang, Sung Son ^a,b   Joo, Won Lee ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

B type natriuretic peptide; Patent ductus arteriosus; Preterm infants; Symptomatic PDA

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN; BIOLOGICAL MARKER;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COLOR ULTRASOUND FLOWMETRY; CONCENTRATION RESPONSE; DIAGNOSTIC VALUE; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; KOREA; MAJOR CLINICAL STUDY; MALE; PATENT DUCTUS ARTERIOSUS; PEPTIDE ANALYSIS; PREMATURITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; NEWBORN; PROSPECTIVE STUDY; ROC CURVE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 20344380200     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-1837     Document Type: Article

References (34)

1. Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr. 1978;92:467-473
2. Stefano JL, Abbasi S, Pearlman SA, Spear ML, Esterly KL, Bhutani VK. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. Am Rev Respir Dis. 1991;143:236-239
3. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2003;88:F464-F466
4. Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, Schmidt B. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med. 1995;149:1136-1141
5. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health. 1994;30:406-411
6. Urquhart DS, Nicholl RM. How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? Arch Dis Child. 2003;88:85-86
7. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol. 2001;6:49-61
8. Evans N. Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants. Adv Neonatal Care. 2003;3:168-177
9. Pesonen E. Role of natriuretic hormones in the diagnosis of patent ductus arteriosus in newborn infants. Acta Paediatr. 2001;90:363-365
10. Holmstrom H, Omland T. Natriuretic peptides as markers of patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002;103:79-80
11. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr. 2001;90:184-191
12. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002;103:75-77
13. Lee JY, Seo WH, Choi BM, et al. Changes of plasma brain natriuretic peptide according to the changes of ductal shunt in healthy preterm infants. J Korean Pediatr Cardiol. 2003;7:128-137
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083
15. Suzumura H, Nitta A, Tanaka G, Arisaka O. Diastolic flow velocity of the left pulmonary artery of patent ductus arteriosus in preterm infants. Pediatr Int. 2001;43:146-151
16. Nakao K, Mukoyama M, Hosoda K, et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 1991;69:1500-1506
17. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203
18. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96
19. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328
20. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96: 1280-1287
21. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825-832
22. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516
23. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl. 1999;230:132-142
24. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ. 1998;317:516-519
25. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865-870
26. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941
27. Cheng V, Kazanagra R, Garcia A, et al. Rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391
28. Maisel AS. Use of BNP levels in monitoring hospitalized heart failure patients with heart failure. Heart Fail Rev. 2003;8:339-344
29. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355:1126-1130
30. Ootaki Y, Yamaguchi M, Yoshimura N, Oka S, Yoshida M, Hasegawa T. Secretion of A-type and B-type natriuretic peptides into the bloodstream and pericardial space in children with congenital heart disease. J Thorac Cardiovasc Surg. 2003;126:1411-1416
31. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45:249-254
32. Yoshibayashi M, Kamiya T, Saito Y, et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol. 1995;133:207-209
33. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart. 2003;89:875-878
34. Silverman NH, Lewis AB, Heymann MA, Rudolph AM. Echocardiographic assessment of ductus arteriosus shunt in premature infants. Circulation. 1974;50:821-825